Cure8 research brief
Financial barriers are common among US adults with IBD and are linked to delayed care and skipping medications — problems that can worsen disease control and quality of life.
Adult patients with IBD (especially those under 65, uninsured, low-income, or living in the South), clinicians who manage IBD, health services researchers, and patient advocacy groups.
This study used National Health Interview Survey data from 2015-16 and 2023-24 and matched adults with IBD to similar controls to compare eight measures of financial hardship. Overall financial hardship, delayed care due to cost, and cost-related medication nonadherence were all higher among people with IBD.
Younger adults (<65), people living in the South, lower-income individuals, and the uninsured had higher odds of hardship. Some measures (problems paying medical bills and medication nonadherence) improved modestly over time, while others did not.
The analysis is based on nationally representative survey data and adjusted matching; it describes associations rather than proving causation. The authors conclude that research is needed to develop interventions to reduce financial hardship in people with IBD.
Findings come from matched analyses of the National Health Interview Survey (2015-16 and 2023-24). The study is observational and reports associations from self-reported survey data rather than clinical outcomes or causal effects.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Shifting to patient-initiated, digitally supported follow-up could maintain disease control while reducing routine fixed-interval visits and improving patient experience — relevant as IBD patient numbers grow and clinic...
Avoidable unplanned hospital admissions are common and costly for people with IBD. This study suggests many such admissions stem from healthcare access and service delivery problems—not just disease severity—so system...
Biosimilars can expand access to effective biologic treatment for people with IBD by reducing costs, but adoption barriers mean some patients may not benefit. Understanding evidence, practical concerns, and...
